Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Epoprostenol
Drug ID BADD_D00788
Description A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.
Indications and Usage For the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.
Marketing Status approved
ATC Code B01AC09
DrugBank ID DB01240
KEGG ID D00106
MeSH ID D011464
PubChem ID 5282411
TTD Drug ID D0V0IX
NDC Product Code 66215-402; 62756-060; 66215-403; 62287-123; 62756-059
UNII DCR9Z582X0
Synonyms Epoprostenol | Epoprostanol | Prostaglandin I2 | Prostacyclin | Prostaglandin I(2) | Veletri | Epoprostenol Sodium | Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer | Flolan
Chemical Information
Molecular Formula C20H32O5
CAS Registry Number 35121-78-9
SMILES CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infestation23.11.01.002; 11.09.01.001--Not Available
Limb discomfort15.03.04.0140.000304%Not Available
Malnutrition14.03.02.0040.000206%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.001587%
Pulmonary vascular disorder24.03.08.003; 22.06.03.0020.000082%Not Available
Ill-defined disorder08.01.03.0490.000164%Not Available
Blood disorder01.05.01.004--Not Available
Disease progression08.01.03.0380.001645%
Sinus disorder22.04.06.0020.000222%
Application site hypersensitivity12.07.01.014; 10.01.03.009; 08.02.01.0130.000082%Not Available
Device related infection11.01.08.018; 08.07.01.005--
Infusion site extravasation12.07.05.008; 08.02.05.0070.000263%
Pulmonary arterial hypertension24.08.03.003; 22.06.01.0020.004153%Not Available
Infusion site haemorrhage24.07.01.058; 12.07.05.018; 08.02.05.0180.000304%Not Available
Infusion site irritation12.07.05.011; 08.02.05.0100.000280%Not Available
Adverse reaction08.06.01.0180.000123%Not Available
Low birth weight baby18.04.02.0030.000164%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.000304%
Hepatic cancer16.07.02.004; 09.04.02.0080.000164%Not Available
Complication associated with device08.07.01.0110.002286%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000452%
Device related thrombosis24.01.01.027; 08.07.05.0010.000123%Not Available
Anal incontinence17.05.01.021; 07.01.06.0290.000321%
Concomitant disease aggravated08.01.03.0630.000247%Not Available
Normal newborn18.08.06.0010.000123%Not Available
Pancreatic cyst16.05.01.005; 07.18.03.0030.000082%Not Available
Post-traumatic stress disorder19.06.06.0020.000181%Not Available
Concomitant disease progression08.01.03.0640.000082%Not Available
The 12th Page    First    Pre   12 13 14    Next   Last    Total 14 Pages